Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai In-licenses KRAS Inhibitor from Mirati in $338 Million Deal

publication date: Jun 1, 2021

Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati (NSDQ: MRTX) of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to $273 million in milestones, plus royalties. Mirati has registration-enabling studies of the candidate underway in NSCLC and colorectal cancer. Last week, Amgen was approved for US launch of its KRAS inhibitor, a target that was once considered undruggable. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688) (NSDQ: AMGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.